Jason Duncan Net Worth

The estimated Net Worth of Jason Duncan is at least $1.06 Million dollars as of 23 January 2023. Mr. Duncan owns over 228 units of Albireo Pharma Inc stock worth over $624,546 and over the last 6 years he sold ALBO stock worth over $437,493. In addition, he makes $0 as Chief Legal Officer, General Counsel und Secretary at Albireo Pharma Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Duncan ALBO stock SEC Form 4 insiders trading

Jason has made over 17 trades of the Albireo Pharma Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 228 units of ALBO stock worth $9,986 on 23 January 2023.

The largest trade he's ever made was exercising 16,300 units of Albireo Pharma Inc stock on 24 June 2021 worth over $396,416. On average, Jason trades about 1,301 units every 50 days since 2018. As of 23 January 2023 he still owns at least 14,146 units of Albireo Pharma Inc stock.

You can see the complete history of Mr. Duncan stock trades at the bottom of the page.

Jason Duncan biography

Jason G. Duncan serves as Chief Legal Officer, General Counsel, Secretary of the Company. He has served as our Chief Legal Officer since January 2020 and as our General Counsel and Secretary since June 2018. He previously served as General Counsel at Stallergenes Greer Holdings, Inc. from August 2015 to June 2018, where he oversaw all legal activities for the allergy immunotherapy company's Americas business. Previously, from May 2014 to August 2015, Mr. Duncan was Vice President, Head of Compliance and Legal for Sobi, Inc., a global biopharmaceutical company focused on rare inflammatory and genetic diseases. At Sobi, Mr. Duncan was responsible for all legal and compliance matters for the company's North American affiliates, and served on the leadership team. Prior to Sobi, from December 2006 to May 2014, Mr. Duncan held roles of increasing responsibility at EMD Serono, Inc., culminating in his position as Associate General Counsel for Neurology and Discovery.

How old is Jason Duncan?

Jason Duncan is 46, he's been the Chief Legal Officer, General Counsel und Secretary of Albireo Pharma Inc since 2020. There are 20 older and no younger executives at Albireo Pharma Inc. The oldest executive at Albireo Pharma Inc is Davey Scoon, 73, who is the Independent Director.

What's Jason Duncan's mailing address?

Jason's mailing address filed with the SEC is C/O ALBIREO PHARMA, INC., 53 STATE STREET, 19TH FLOOR, BOSTON, MA, 02109.

Insiders trading at Albireo Pharma Inc

Over the last 8 years, insiders at Albireo Pharma Inc have traded over $26,339,822 worth of Albireo Pharma Inc stock and bought 932,623 units worth $30,497,757 . The most active insiders traders include Advisors Llcperceptive Life..., Roger Jeffs und Plcastrazeneca Ab Astrazeneca. On average, Albireo Pharma Inc executives and independent directors trade stock every 19 days with the average trade being worth of $957,260. The most recent stock trade was executed by Pamela Stephenson on 23 January 2023, trading 102 units of ALBO stock currently worth $4,468.

What does Albireo Pharma Inc do?

Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo's lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year.

Complete history of Mr. Duncan stock trades at Albireo Pharma Inc

Albireo Pharma Inc executives and stock owners

Albireo Pharma Inc executives and other stock owners filed with the SEC include:

• Ronald Cooper,
  President, Chief Executive Officer, Director
• Pamela Stephenson,
  Chief Commercial Officer
• Jan Mattsson,
  Chief Scientific Officer
• Martha Carter,
  Chief Regulatory Officer
• Ronald H. W. Cooper,
  CEO, Pres & Director
• Patrick Horn,
  Chief Medical Officer
• Martha J. Carter,
  Chief Regulatory Officer
• Simon Nicolas Reade Harford,
  CFO & Treasurer
• David Chiswell,
  Independent Chairman of the Board
• Davey Scoon,
  Independent Director
• Michael Gutch,
  Independent Director
• Roger Jeffs,
  Independent Director
• Stephanie Okey,
  Independent Director
• Anne Klibanski,
  Independent Director
• Jason Duncan,
  Chief Legal Officer, General Counsel, Secretary
• Michelle Graham,
  Chief Human Resource Officer
• Simon Harford,
  Chief Financial Officer, Treasurer
• Jason G. Duncan,
  Chief Legal Officer, Gen. Counsel & Sec.
• Pamela Stephenson M.P.H.,
  Chief Commercial Officer
• Dr. Kristina Torfgard,
  VP & Global Project Head
• Michelle Graham,
  Chief HR Officer
• Joan Connolly,
  Chief Technology Officer
• Dr. Jan P. Mattsson Ph.D.,
  Chief Scientific Officer, MD (Sweden) & Co-Founder
• Dr. Per-Goran Gillberg,
  Co-Founder & VP of Devel.
• Denise Scots Knight,
  Director
• Julia R Brown,
  Director
• Heather Preston,
  Director
• Paresh Soni,
  Chief Medical Officer
• Thomas A. Shea,
  CFO and Treasurer
• Peter A Zorn,
  Senior VP, Corp Dev, GC & Sec
• Plcastrazeneca Ab Astrazeneca,
  
• Paul Streck,
  Chief Medical Officer
• Advisors Llcperceptive Life...,
  
• Partners Ltd Phase4 Venture...,
  
• Craig C. Hopkinson,
  Director
• Susan Alesina,
  Director
• Habib J Dable,
  Director